Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus endocrine therapy in high-risk HR-positive/HER2-negative early breast cancer
NL-OMON45456Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib + endocrine therapy with Placebo + endocrine therapy (2 arms). Primary endpoint: Invasive disease-free survival. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45456.